BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 9555668)

  • 1. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency.
    Patruta SI; Edlinger R; Sunder-Plassmann G; Hörl WH
    J Am Soc Nephrol; 1998 Apr; 9(4):655-63. PubMed ID: 9555668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
    Riedel MK; Morgenstern T
    Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO.
    Mittman N; Sreedhara R; Mushnick R; Chattopadhyay J; Zelmanovic D; Vaseghi M; Avram MM
    Am J Kidney Dis; 1997 Dec; 30(6):912-22. PubMed ID: 9398141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients.
    Chiang WC; Tsai TJ; Chen YM; Lin SL; Hsieh BS
    Clin Nephrol; 2002 Nov; 58(5):363-9. PubMed ID: 12425487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Assessment of iron requirements during treatment of anemia with recombinant human erythropoietin in patients with chronic renal insufficiency under hemodialysis].
    Oliveira C; Boquinhas H; Gaspar A; Adragão T; Boquinhas JM; Júnior EC; Simões J
    Acta Med Port; 1992 Jul; 5(7):351-7. PubMed ID: 1442178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin (EPO).
    Saltissi D; Sauvage D; Westhuyzen J
    Clin Nephrol; 1998 Jan; 49(1):45-8. PubMed ID: 9491286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
    Chen YC; Hung SC; Tarng DC
    Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis.
    Susantitaphong P; Alqahtani F; Jaber BL
    Am J Nephrol; 2014; 39(2):130-41. PubMed ID: 24513913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unanticipated favorable effects of correcting iron deficiency in chronic hemodialysis patients.
    Pollak VE; Lorch JA; Means RT
    J Investig Med; 2001 Mar; 49(2):173-83. PubMed ID: 11288758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron supplementation in haemodialysis--practical clinical guidelines.
    Silva J; Andrade S; Ventura H; Santos JP; Colaço S; Oliveira C; Ponce P
    Nephrol Dial Transplant; 1998 Oct; 13(10):2572-7. PubMed ID: 9794562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience with zinc protoporphyrin as a marker of endogenous iron availability in chronic haemodialysis patients.
    Baldus M; Salopek S; Möller M; Schliesser J; Klooker P; Reddig J; Gansert U; Brass H
    Nephrol Dial Transplant; 1996 Mar; 11(3):486-91. PubMed ID: 8710158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a low-dose intravenous iron sucrose regimen in peritoneal dialysis patients.
    Dittrich E; Schillinger M; Sunder-Plassmann G; Hörl WH; Vychytil A
    Perit Dial Int; 2002; 22(1):60-6. PubMed ID: 11929146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Content of reticulocyte hemoglobin is a reliable tool for determining iron deficiency in dialysis patients.
    Tsuchiya K; Okano H; Teramura M; Iwamoto Y; Yamashita N; Suda A; Shimada K; Nihei H; Ando M
    Clin Nephrol; 2003 Feb; 59(2):115-23. PubMed ID: 12608554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients.
    Kaneko Y; Miyazaki S; Hirasawa Y; Gejyo F; Suzuki M
    Kidney Int; 2003 Mar; 63(3):1086-93. PubMed ID: 12631092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation.
    Fishbane S; Frei GL; Maesaka J
    Am J Kidney Dis; 1995 Jul; 26(1):41-6. PubMed ID: 7611266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin and iron.
    Sunder-Plassmann G; Hörl WH
    Clin Nephrol; 1997 Mar; 47(3):141-57. PubMed ID: 9105761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The utility of zinc protoporphyrin for predicting the need for intravenous iron therapy in hemodialysis patients.
    Fishbane S; Lynn RI
    Am J Kidney Dis; 1995 Mar; 25(3):426-32. PubMed ID: 7872320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
    Frankenfield DL; Johnson CA
    Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing.
    Diebold M; Kistler AD
    BMC Nephrol; 2019 Mar; 20(1):76. PubMed ID: 30823916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of iron status by erythrocyte ferritin in uremic patients with or without recombinant human erythropoietin therapy.
    Caravaca F; Vagace JM; Aparicio A; Groiss J; Pizarro JL; Alonso N; Garcia MC; Arrobas M; Cubero J; Esparrago J
    Am J Kidney Dis; 1992 Sep; 20(3):249-54. PubMed ID: 1519605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.